Tumor Microenvironment Composition and Severe Cytokine Release Syndrome (CRS) Influence Toxicity in Patients with Large B-Cell Lymphoma Treated with Axicabtagene Ciloleucel.
Rawan FaramandMichael D JainVerena StaedtkeHiroshi KotaniRenyuan BaiKayla ReidSae Bom LeeKristen SpitlerXuefeng WangBiwei CaoJavier PinillaAleksander LazaryanFarhad KhimaniBijal ShahJulio C ChavezTaiga NishihoriAsmita MishraJohn E MullinaxRicardo GonzalezMohammad HussainiMarian DamBrigett D BrandjesChristina A BachmeierClaudio AnasettiFrederick L LockeMarco L DavilaPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
These results suggest that a proinflammatory state and an unfavorable TME preemptively put patients at risk for toxicity after CAR T-cell therapy. Tailoring toxicity management strategies to patient risk may reduce morbidity and mortality.